Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study
Publication
, Conference
Kalunian, K; Clowse, MEB; Houssiau, F; Petri, MA; Kilgallen, B; Gordon, C; Strand, V; Bongardt, S; Wallace, DJ
Published in: ARTHRITIS AND RHEUMATISM
October 1, 2013
Duke Scholars
Published In
ARTHRITIS AND RHEUMATISM
EISSN
1529-0131
ISSN
0004-3591
Publication Date
October 1, 2013
Volume
65
Start / End Page
S738 / S738
Location
San Diego, CA
Publisher
WILEY-BLACKWELL
Conference Name
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals
Related Subject Headings
- Arthritis & Rheumatology
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kalunian, K., Clowse, M. E. B., Houssiau, F., Petri, M. A., Kilgallen, B., Gordon, C., … Wallace, D. J. (2013). Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study. In ARTHRITIS AND RHEUMATISM (Vol. 65, pp. S738–S738). San Diego, CA: WILEY-BLACKWELL.
Kalunian, Kenneth, Megan E. B. Clowse, Frederic Houssiau, Michelle A. Petri, Brian Kilgallen, Caroline Gordon, Vibeke Strand, Sabine Bongardt, and Daniel J. Wallace. “Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study.” In ARTHRITIS AND RHEUMATISM, 65:S738–S738. WILEY-BLACKWELL, 2013.
Kalunian K, Clowse MEB, Houssiau F, Petri MA, Kilgallen B, Gordon C, et al. Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study. In: ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL; 2013. p. S738–S738.
Kalunian, Kenneth, et al. “Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study.” ARTHRITIS AND RHEUMATISM, vol. 65, WILEY-BLACKWELL, 2013, pp. S738–S738.
Kalunian K, Clowse MEB, Houssiau F, Petri MA, Kilgallen B, Gordon C, Strand V, Bongardt S, Wallace DJ. Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study. ARTHRITIS AND RHEUMATISM. WILEY-BLACKWELL; 2013. p. S738–S738.
Published In
ARTHRITIS AND RHEUMATISM
EISSN
1529-0131
ISSN
0004-3591
Publication Date
October 1, 2013
Volume
65
Start / End Page
S738 / S738
Location
San Diego, CA
Publisher
WILEY-BLACKWELL
Conference Name
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals
Related Subject Headings
- Arthritis & Rheumatology
- 1117 Public Health and Health Services
- 1107 Immunology
- 1103 Clinical Sciences